

Substitute for form 1449A/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Application No.	10/773,356
		Filing Date	February 5, 2004
		First Named Inventor	Weiner et al.
		Art Unit	1644
		Examiner Name	EWOLDT
Sheet	1	of	3
		Attorney Docket Number	23714-07992/US

*Sent 7/21/04*

U.S. PATENT DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Document No. Number - Kind Code <sup>2</sup> (if known)	Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
<i>EW</i>	A1	US-5,849,886	12-15-1998	MAATTA ET AL

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> - Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	T <sup>6</sup>
		WO 91/015225	17-10-1991	BRIGHAM AND WOMEN'S HOSPITAL ET AL	
		WO 90/010449	20-09-1990	COHEN ET AL	
		WO 03/024393 A2	12-09-2002	OPEXA PHARMACEUTICALS ET AL	

OTHER REFERENCES - NON-PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>6</sup>
		ACHA-ORBEA, H., et al., "Limited heterogeneity of T cell receptors from lymphocytes mediating autoimmune encephalomyelitis allows specific immune intervention," <i>Cell</i> , (1988) 54: 283-273	
		BEN-NUN, A. ET AL. "The autoimmune reactivity to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis is potentially pathogenic: effect of copolymer 1 on MOG-induced disease." <i>J. Neurol</i> (1996) 243(Suppl 1):S14-S22	
		BEN-NUN, A., ET AL., "Restricted T-Cell receptor Vβ gene usage by myelin base protein-specific T-Cell clones in multiple sclerosis: Predominant genes vary in individuals," <i>Proc. Nat. Acad. Sci USA</i> (1991) 88: 2466-2470	
		BOURDETTE, D.N., ET AL., "Immunity to TCR peptides in multiple sclerosis. I. Successful immunization of patients with synthetic Vβ5.2 and Vβ6.1 CDR2 peptides," <i>J. Immunol.</i> (1994) 152:2510-2519	
		CHOU, Y.K., ET AL., "Immunity to TCR peptides in multiple sclerosis. II. T Cell Recognition of Vβ5.2 and Vβ6.1 CDR2 peptides," <i>J. Immunol.</i> (1994) 152:2520-2529	
<i>EW</i>		COHEN, PL. "Systemic autoimmunity" from <i>Fundamental Immunology</i> , (1999) pages 1067 and 1083. William E. Paul, editor, Lippencott-Raven, Publishers.	

Examiner Signature	<i>EW</i> 12/14/05	Date Considered	
--------------------	--------------------	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609.  
Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO			<b>Complete if Known</b>		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>			Application No.	10/773,356	
			Filing Date	February 5, 2004	
			First Named Inventor	Weiner et al.	
			Art Unit	1644	
			Examiner Name	EWOLDT	
Sheet	2	of	3	Attorney Docket Number	23714-07992/US

Sent 7/21/04

OTHER REFERENCES - NON-PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.†	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T*
LJH		CORREALE, J., ET AL. "Isolation and characterization of CD8+ T-cell clones (TCCs) that recognize autologous-activated CD4+ TCCs from chronic progressive multiple sclerosis (MS) patients: implications for immunoregulation in MS," <i>Neurology</i> , (February 1996) 46: Suppl. S, p. A280	
		CORREALE, J. ET AL. "T-cell vaccination in secondary progressive multiple sclerosis," <i>Journal of Neuroimmunology</i> , (2000) 107:130-139.	
		GOLD, D.P., ET AL., "Results of a phase 1 clinical trial of a T-cell receptor vaccine in patients with multiple sclerosis. II. Comparative analysis of TCR utilization in CSF T-cell populations before and after vaccination with a TCR Vβ6 CDR 2 peptide," <i>J. Neuroimmunol.</i> , (1997) 76 pp. 29-38.	
		HAFNER, D.A., ET AL. "T cell vaccination in multiple sclerosis: A preliminary report," <i>Clin. Immunol Immunopath.</i> (1992) 62(3), pp. 307-313	
		HOWELL, M.D., ET AL. "Vaccination against experimental allergic encephalomyelitis with T cell receptor peptides," <i>Science</i> , (1989) 246:658-670.	
		LIBLAU, R., ET AL., "T cell response to myelin basic protein epitopes in multiple sclerosis patients and healthy subjects," <i>Eur. J. Immunol.</i> , (1991) 21:1391-1395.	
		LOHSE, A.W., ET AL. "Control of experimental autoimmune encephalomyelitis by T cells responding to activated T cells," <i>Science</i> (1989) 244:820-822.	
		MEDAER, R., ET AL. "Prospects for T cell vaccination in multiple sclerosis," <i>BioDrugs</i> , (1997), 8:1-5.	
		MILLER, STEPHEN D., ET AL. "The immunopathogenesis and regulation of T-cell mediated demyelinating disease," <i>Immunology Today</i> , (1994) 15:356-361.	
		MORELAND, L., ET AL. "Vaccination against rheumatoid arthritis," <i>BioDrugs</i> , (1997) 8:87-85.	
		STINISSEN, P., ET AL. "Vaccination with autoreactive T cell clones in multiple sclerosis: Overview of immunological and clinical data," <i>Journal of Neuroscience Research</i> (1996) 45:500-511.	
		VAN DER AA ET AL. "T cell vaccination in multiple sclerosis patients with autologous CSF derived activated T cells: results from a pilot study," <i>Clin. Exp. Immunol.</i> (2003) 131:155-168.	
LJH		VAN LAAR, J., ET AL. "Effects of inoculation with attenuated autologous T cells in patients with rheumatoid arthritis," <i>Journal of Autoimmunity</i> , (1993) 6:159-167	

Examiner Signature	<i>LJH</i> 7/21/04	Date Considered	
--------------------	--------------------	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608.  
Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

†Applicant's unique citation designation number (optional). \*See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. †Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). †For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. \*Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>Sent 7/21/04</i>			<b>Complete if Known</b>		
			Application No.	10/773,356	
			Filing Date	February 5, 2004	
			First Named Inventor	Weiner et al.	
			Art Unit	1644	
			Examiner Name	EWOLDT	
Sheet	3	of	3	Attorney Docket Number	23714-07992/US

OTHER REFERENCES – NON-PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.†	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
<i>FW</i>		VANDENBARK, A.A., ET AL. "T Cell receptor peptides in treatment of autoimmune disease: rational and potential," <u>J. Neurosci. Res.</u> , (1996) 43:391-402	
		VANDENBARK, A.A., ET AL. "Immunization with a synthetic T-cell receptor V-region peptide protects against experimental autoimmune encephalomyelitis," <u>Nature</u> (1989) 341:541-544	
		WEINER, L., ET AL., "Isolation and characterization of CD8+ and gamma-delta T cells specific for autologous autoreactive CD4+ T cell clones from multiple sclerosis patients and healthy control subjects," <u>Neurology</u> , (March 1997), 48 (3) Suppl. 2, pp. A59-A60	
		ZHANG, J., ET AL. "T-cell vaccination in autoimmune diseases – from laboratory to clinic," <u>Human Immunol.</u> (1993) 38, pp. 87-96	
		ZHANG, J., J., ET AL. "MHC-restricted depletion of human myelin basic protein-reactive T cells by T cell vaccination," <u>Science</u> , (1993) 261:1451-1454	
		ZHANG, J., ET AL. "Myelin basic protein-reactive T cells in multiple sclerosis: pathologic relevance and therapeutic targeting," <u>Cytotechnology</u> (1994) 16:181-187	
		ZHANG ET AL. In vivo clonotypic regulation of human myelin basic protein reactive T cells by T cell vaccination," <u>Journal of Immunology</u> (1995) 155:5868-5877	
<i>JSZ</i>		ZHANG, J. "Multiple Sclerosis: Perspectives on Autoimmune Pathology and Prospects for Therapy," <u>Current Neurology</u> (1995) 15:115-155	

23714/07992/SF/5122822.1

Examiner Signature	<i>JSZ</i>	Date Considered	
--------------------	------------	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609.  
 Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

†Applicant's unique citation designation number (optional). ‡See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. §Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ¶For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \*\*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. \*\*\*Applicant is to place a check mark here if English language Translation is attached.